Skip to content

All Lessons

Reimagining Clinical Research: The Transformation of Trial Design & Conduct 

REMS Logic Model in REMS Design, Implementation, and Evaluation

Request for Reconsideration – Overview and Experience from Bioequivalence Perspectives

Request For Reconsideration: Process Overview and Best Practices for FDA Evaluation

Requesting a Labeler Code from FDA

Rx Drug Promotion and the Clear, Conspicuous, and Neutral Final Rule

Safety Considerations in Clinical Drug Development

Safety Considerations in Clinical Drug Development

Selective Safety Data Collection in Clinical Trials (REdI 2024 – Drugs Track)

Session 1: Panel Discussion (FDA Generic Drug Science Workshop 2025)

Session 1: Presentations (FDA Generic Drug Science Workshop 2025)

Session 1: Q&A Panel (Advancing Generic Drug Development 2025)

Session 1: Question & Answer Panel (Advancing Generic Drug Development 2024)

Session 1: Scientific and Regulatory Considerations for In Vitro Release Test (IVRT) for Complex Products

Session 2: Panel Discussion (FDA Generic Drug Science Workshop 2025)

Session 2: Presentations (FDA Generic Drug Science Workshop 2025)

Session 2: Q&A Panel and Day 1 Closing (Advancing Generic Drug Development 2025)

Session 2: Question & Answer Panel (Advancing Generic Drug Development 2024)

Session 2: Regulatory Pathways for Epinephrine Products, Including Considerations for Prescription and Nonprescription Development

Session 2: Research to Support Guidance Development for Topical Drug Products

Session 3: Panel Discussion (FDA Generic Drug Science Workshop 2025)

Session 3: Presentations (FDA Generic Drug Science Workshop 2025)

Session 3: Q&A Panel (Advancing Generic Drug Development 2025)

Session 3: Question & Answer Panel (Advancing Generic Drug Development 2024)

Session 3: Research to Support Guidance Development for Inhalation Drug Products

1 … 11 12 13 14 15 16
Share: